Drugs / Rotavirus Vaccine, Live, Oral, Pentavalent
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04398706 | May 2020 → Aug 2023 | chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT00130832 | Oct 2005 → Jul 2006 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT00166517 | Aug 2005 → Jul 2006 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03691610 Background | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-05-25 | Merck Sharp & Dohme LLC | Government of Rwanda Introduces Merck’s ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rotavirus Vaccine, Live, Oral, Pentavalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04398706 ↗ |
| Known as | PRV | “The live oral pentavalent rotavirus vaccine (PRV) is well tolerated and highly efficacious against rotavirus gastroenteritis.” PMID 18756184 ↗ Oct 2008 |
| Modality | Vaccine | “The live oral pentavalent rotavirus vaccine (PRV) is well tolerated and highly efficacious against rotavirus gastroenteritis.” PMID 18756184 ↗ Oct 2008 |
| Route | Oral | “Three doses of rotavirus vaccine, live, oral, pentavalent.” NCT00130832 ↗ |